Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer

Nitric Oxide - Biology and Chemistry

Volumn 29, Issue , 2013, Pages 17-24

  Huerta Yepez, Sara ^a,b   Baritaki, Stavroula ^a   Baay Guzman, Guillermina ^b   Hernandez Luna, Marco A ^b   Hernandez Cueto, Angeles ^c   Vega, Mario I ^a,d   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

BclXL; Chemoresistance; Nitric oxide; Prostate cancer; Sensitization; YY1

Indexed keywords

DETANONOATE; NITRIC OXIDE; NITRIC OXIDE DONOR; PROTEIN BCL XL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG; 2,2' (HYDROXYNITROSOHYDRAZONO)BIS ETHANAMINE; 2,2'-(HYDROXYNITROSOHYDRAZONO)BIS-ETHANAMINE; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; NITROSO DERIVATIVE; PROTEIN BCL X; YY1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CELL LYSATE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, NUDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; YY1 TRANSCRIPTION FACTOR;

EID: 84871574629     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2012.12.001     Document Type: Article

References (30)

1. D.S. Tan, M. Gerlinger, B.T. Teh, and C. Swanton Anti-cancer drug resistance. understanding the mechanisms through the use of integrative genomics and fucntional RNA interference Eur. J. Cancer 46 2010 2166 2177
2. A. Garcia, and J.J. Kandel Notch: a key regulator of tumor angiogenesis and metastasis Histol. Histopathol. 27 2012 151 156
3. D.W. Shen, L.M. Pouliot, M.D. Hall, and M.M. Gottesman Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol. Rev. 64 2012 706 721
4. A. Russo, M. Terrasi, V. Agnese, D. Santini, and V. Bazan Apoptosis: a relevant tool for anticancer therapy Ann. Oncol. 17 2006 115 123
5. A. Katsman, K. Umezawa, and B. Bonavida Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent Drug Resist. Updat. 10 2007 1 12
6. B. Bonavida, S. Baritaki, S. Huerta-Yepez, M.I. Vega, D. Chatterjee, and K. Yeung Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 19 2 2008 152 157 (Epub 2008 Apr 24)
7. S. Huerta-Yepez, M. Vega, S.E. Escoto-Chavez, B. Murdock, T. Sakai, and S. Baritaki Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1 Nitric Oxide 20 2009 39 52
8. S. Huerta-Yepez, M. Vega, A. Jazirehi, H. Garban, F. Hongo, and G. Cheng Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression Oncogene 23 2004 4993 5003
9. D.A. Wink, J.A. Cook, D. Christodoulou, M.C. Krishna, R. Pacelli, and S. Kim Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin Nitric Oxide 1 1997 88 94
10. M.I. Vega, S. Huerta-Yepez, M. Martinez-Paniagua, B. Martinez-Miguel, R. Hernandez-Pando, and C.R. González-Bonilla Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions Clin. Cancer Res. 15 2009 6582 6594
11. S. Baritaki, A. Katsman, D. Chatterjee, K.C. Yeung, D.A. Spandidos, and B. Bonavida Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation J. Immunol. 179 2007 5441 5453
12. S. Huerta, G. Baay-Guzman, C.R. Gonzalez-Bonilla, E.H. Livingston, S. Huerta-Yepez, and B. Bonavida In vitro and in vivo sensitication of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: involvement of AIP Nitric Oxide 20 2009 182 194
13. R. Zhang, L. Zhang, Z. Zhang, Y. Wang, M. Lu, M. Lapointe, and M. Chopp A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats Ann. Neurol. 50 2001 602 611
14. J.I. Epstein An update of the Gleason grading system J. Urol. 183 2010 433 440
15. D.B. Seligson, F. Hongo, S. Huerta-Yepez, Y. Mizutani, T. Miki, and H. Yu Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence Clin. Cancer Res. 13 2007 6056 6063
16. M.C. Berenbaum A method for testing for synergy with any number of agents J. Infect. Dis. 137 1978 122 130
17. B. Bonavida, and S. Baritaki Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kappaB/Snail/YY1/RKIP circuitry Nitric Oxide 24 2011 1 7
18. B. Bonavida, S. Baritaki, S. Huerta-Yepez, M.I. Vega, D. Chatterjee, and K. Yeung Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 19 2 2008 152 157
19. L.J. Frederiksen, R. Sullivan, L.R. Maxwell, S.K. Macdonald-Goodfellow, M.A. Adams, and B.M. Bennett Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling Clin. Cancer Res. 13 2007 2199 2206
20. R. Sullivan, and C.H. Graham Chemosensitization of cancer by nitric oxide Curr. Pharm. Des. 14 2008 1113 1123
21. D. Seligson, S. Horvath, S. Huerta-Yepez, S. Hanna, H. Garban, and A. Roberts Expression of transcription factor Yin Yang 1 in prostate cancer Int. J. Oncol. 27 2005 131 141
22. A. Sun, J. Tang, Y. Hong, J. Song, P.F. Terranova, and J.B. Thrasher Androgen receptor-dependent regulation of Bcl-xL expression: implication in prostate cancer progression Prostate 68 2008 453 461
23. M.I. Vega, A.R. Jazirehi, S. Huerta-Yepez, and B. Bonavida Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively J. Immunol. 175 2005 2174 2183
24. H.E. Marshall, D.T. Hess, and J.S. Stamler S-nitrosylation: physiological regulation of NF-kappaB Proc. Natl. Acad. Sci. U.S.A. 101 2004 8841 8842
25. C. Gabellini, L. Castellini, D. Trisciuoglio, M. Kracht, G. Zupi, and D. Del Bufalo Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma J. Neurochem. 107 2008 871 882
26. I. Lebedeva, R. Rando, J. Ojwang, P. Cossum, and C.A. Stein Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity Cancer Res. 60 2000 6052 6060
27. I. Lebedeva, A. Raffo, R. Rando, J. Ojwang, P. Cossum, and C.A. Stein Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides J. Urol. 166 2001 461 469
28. M.A. Martinez-Paniagua, S. Baritaki, S. Huerta-Yepez, V.F. Ortiz-Navarrete, C. González-Bonilla, and B. Bonavida Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis Cell Cycle 10 2011 2792 2805
29. Y. Meng, W. Tang, Y. Dai, X. Wu, M. Liu, and Q. Ji Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa Mol. Cancer Ther. 7 2008 2192 2202
30. M.Q. Baggstrom, Y. Qi, M. Koczywas, A. Argiris, E.A. Johnson, and M.J. Millward A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer J. Thorac. Oncol. 6 2011 1757 1760